Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status
(Q37244802)
scientific article published on 03 September 2013
scientific article published on 03 September 2013
Language: